EU ‘negotiating with Valneva’ over COVID-19 vaccine contractThe European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to Share XEU ‘negotiating with Valneva’ over COVID-19 vaccine contracthttps://pharmaphorum.com/news/eu-negotiating-with-valneva-over-covid-19-vaccine-contract/
Valneva slumps as UK dumps €1.4bn order for COVID-19 jabThe UK has terminated its order for up to 190 million doses of a COVID-19 vaccine developed by Share XValneva slumps as UK dumps €1.4bn order for COVID-19 jabhttps://pharmaphorum.com/news/valneva-slumps-as-uk-dumps-e1-4bn-order-for-covid-19-jab/
Biogen admits slow Aduhelm launch, as scientists question label againShares in Biogen have come under pressure after chief executive Michel Vounatsos admitted that the company is facing Share XBiogen admits slow Aduhelm launch, as scientists question label againhttps://pharmaphorum.com/news/biogen-admits-slow-aduhelm-launch-as-scientists-question-label-again/
Sanofi snaps up Kadmon and its transplant drug RezurockLess than a month after Kadmon Pharma launched its first product – Rezurock for a complication of organ Share XSanofi snaps up Kadmon and its transplant drug Rezurockhttps://pharmaphorum.com/news/sanofi-snaps-up-kadmon-and-its-transplant-drug-rezurock/
Mallinckrodt moves closer to resolving its opioid liability hangoverMallinckrodt looks like it could join Purdue Pharma in reaching a settlement in its bankruptcy proceedings related to Share XMallinckrodt moves closer to resolving its opioid liability hangoverhttps://pharmaphorum.com/news/mallinckrodt-moves-closer-to-resolving-its-opioid-liability-hangover/
EU and AstraZeneca resolve COVID-19 vaccine supply spatAstraZeneca’s legal dispute with the European Commission over a shortfall in the supply of COVID-19 vaccines promised by Share XEU and AstraZeneca resolve COVID-19 vaccine supply spathttps://pharmaphorum.com/news/eu-astrazeneca-reach-resolution-in-covid-19-supply-spat/
Purdue bankruptcy court hands immunity to Sackler familyA US federal judge has approved a bankruptcy settlement for Purdue Pharma that grants the Sackler family that Share XPurdue bankruptcy court hands immunity to Sackler familyhttps://pharmaphorum.com/news/purdue-bankruptcy-court-hands-immunity-to-sackler-family/
FDA clears J&J’s twice-yearly Invega for schizophreniaOne of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Share XFDA clears J&J’s twice-yearly Invega for schizophreniahttps://pharmaphorum.com/news/fda-clears-jjs-twice-yearly-invega-for-schizophrenia/
Galapagos’ long-serving CEO Onno van de Stolpe to retireAfter 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided Share XGalapagos’ long-serving CEO Onno van de Stolpe to retirehttps://pharmaphorum.com/news/galapagos-long-serving-ceo-onno-van-de-stolpe-to-retire/
Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T caseGilead Sciences’ Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Share XAppeals court reverses $1.2bn judgment against Gilead in BMS CAR-T casehttps://pharmaphorum.com/news/appeals-court-reverses-1-2bn-judgment-against-gilead-in-bms-car-t-case/
Europe has its first Lucentis biosimilar, Samsung Bioepis’ ByoovizNovartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission Share XEurope has its first Lucentis biosimilar, Samsung Bioepis’ Byoovizhttps://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/
Alex Gorsky will pass leadership of J&J to Joaquin Duato in JanuaryJohnson & Johnson has appointed Joaquin Duato as chief executive officer to replace long-serving Alex Gorsky, who has Share XAlex Gorsky will pass leadership of J&J to Joaquin Duato in Januaryhttps://pharmaphorum.com/news/alex-gorsky-will-pass-leadership-of-jj-to-joaquin-duato-in-january/
Years after Pfizer merger, ex-Medivation exec gets insider trading chargeA Medivation executive at the heart of the company’s team that sold the company to Pfizer for $14 Share XYears after Pfizer merger, ex-Medivation exec gets insider trading chargehttps://pharmaphorum.com/news/years-after-pfizer-merger-ex-medivation-exec-gets-insider-trading-charge/
Novartis says trials back Beovu safety in diabetic eye diseaseThere is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to Share XNovartis says trials back Beovu safety in diabetic eye diseasehttps://pharmaphorum.com/news/novartis-says-trials-back-beovu-safety-in-diabetic-eye-disease/
As the smoke clears, Vectura backs tobacco giant PMI’s bidVectura’s board has decided to recommend a takeover bid from tobacco giant Philip Morris International, despite being urged Share XAs the smoke clears, Vectura backs tobacco giant PMI’s bidhttps://pharmaphorum.com/news/as-the-smoke-clears-vectura-backs-tobacco-giant-pmis-bid/
UK cues up more Pfizer/BioNTech vaccines as price row loomsThe UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order Share XUK cues up more Pfizer/BioNTech vaccines as price row loomshttps://pharmaphorum.com/news/uk-cues-up-more-pfizer-biontech-vaccines-as-price-row-looms/
Update: Carlyle baulks at Vectura auction, urges shareholders to back its bidPrivate equity group Carlyle has said it won’t raise its offer for respiratory drug specialist Vectura to match Share XUpdate: Carlyle baulks at Vectura auction, urges shareholders to back its bidhttps://pharmaphorum.com/news/carlyle-baulks-at-vectura-auction-but-urges-shareholders-to-back-its-bid/
Gene therapy specialist bluebird exits “untenable” European marketEurope market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene Share XGene therapy specialist bluebird exits “untenable” European markethttps://pharmaphorum.com/news/gene-therapy-specialist-bluebird-exits-untenable-european-market/
